留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

慢性乙型肝炎的抗病毒研究进展

操跃,  钱其军

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 561-565
操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022
  • 1.

    福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

  • 2.

    第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438

Progress in study of antiviral effect of chronic hepatitis B

  • 1.

    First Clinical Medical College, Fujian Medical University, Fuzhou 350108, China;Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • 2.

    Laboratory of Gene and Viral Therapy, Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital Affiliated to Second Military Medical University, Shanghai 200438, China

  • 摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。
    Abstract: Chronic hepatitis B is a worldwide infectious diseases caused by hepatitis B virus (HBV). HBV infection is an important reason for liver cirrhosis and liver cancer in our country. Currently, the interferon and nucleoside analogs antiviral drugs (nucleotides) is widely used in clinical practice. These drugs inhibit the replication of the virus and disease development to a certain extent, but not fundamentally eliminate the virus. Various therapeutic vaccines have also made certain curative effect in anti HBV, but the effect is not perfect clinically. At present, many research Results demonstrate that biological immunotherapy can successfully eliminate HBV virus in the body, therefore it has brought a new hope for the treatment of hepatitis B.
  • [1] Robinson WS, Lutwick LI, et al. The virus of hepatitis, type B(fist of two parts)[J]. N Engl J Med,1976,295:1168-1175.
    [2] Ito K, Qin Y, Guarnieri M, et al.Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein andrescue by a novel glycosylation site[J]. Virol,2010,84:12850-12861.
    [3] Shin D, Kim SI, Kim M, et al.Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene inmice[J]. Virus Res,2006,119:146-153.
    [4] Roingeard P,Lu SL,Sureau C,et al.Immunocytochemical and electron microscopic study of hepatitis B virus antigen and complete particle production in hepatitis B virus DNA transfected HepG2 cells[J].Hepatology,1990,11(2):277-285.
    [5] Kanto T,Inoue M,Miyatake H,et al.Reduced number impaired ability of myeloid and plasmacytoid dendritic cell polarize T helper cells in chronic hepatitis C virus infection[J].J Infect Dis,2004,190(11):1919-1926.
    [6] van der Molen RG,Sprengers D,Binda RS,et al .Function impairment of myeloid and plasmacytoid dendritic cells tients with chronic hepatitis B[J].Hepatology,2004,40(3):738-746.
    [7] Stoop JN,van der Molen RG,Baan CC,et al.Regulatory cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection[J].Hepatology,2005,41(4):771-778.
    [8] Xu D,Fu J,Jin L,et al.Circulating and liver resident CD4,CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B[J].J Immunol, 2006,177(1):739-747.
    [9] Sandalova E,Laccabue D,Boni C,et al.Increased levels of arginase in patients with acute hepatitis B suppress antiviral T cells[J].Gastroenterology,2012,143(1):78-87.
    [10] Zhang Z,Zhang S,Zou Z,et al.Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients[J].Hepatology,2011,53(1):73-85.
    [11] Fattovich G, Stroffolini T, Zagni I,et al.Hepatocellular carcinoma in cirrhosis: incidence and risk factors[J]. Gastroenterology,2004,127(5 suppl 1): S35-S50.
    [12] Janssen HL, van Zonneveld M, Senturk H,et al.Pegylated interferon-alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:arandomised trial[J].Lancet, 2005,365(9454):123-129.
    [13] Lau GK, Piratvisuth T, Luo KX,et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B[J].N Engl J Med, 2005,352(26):2682-2695.
    [14] Dienstag JL.Drug therapy: hepatitis B virus infection[J].N Engl J Med,2008,359:1486-500.
    [15] Gish RG, Lok AS, Chang TT,et al. Entecavir therapy for up to 96 weeks inpatients with HBeAg-positive chronic hepatitis B[J]. Gastroenterology,2007,133: 1437-1444.
    [16] Zoutendijk R, Reijnders JG, Zoulim F,et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut,2013,62: 760-765.
    [17] Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon-alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B.An Italian multicenter, randomized trial[J]. Hepatol,2001,35:406-411.
    [18] Petersen J, Ratziu V, Buti M,et al.Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study[J]. Hepatol,2012,56(3): 520-526.
    [19] Michel ML, Tiollais P. Hepatitis B vaccines: protective efficacy and the rapeutic potential[J].Pathol Biol,2010, 58(4):288-295.
    [20] Sheppard CW, Samar EP,Finely L,et al.Hepatitis B virus infection: epidemiol and vaccination[J].Epidemiol Rev,2006,28:112-125.
    [21] Chen HL, Chang MH, Ni YH, et al. Seroepidemiology of hepatitis B virus infection in children: ten years of mass vaccination in Taiwan[J]. JAMA,1996, 276(11):906-908.
    [22] 贺学新.非核苷类似药物在慢性乙肝治疗中的应用[J].现代医药卫生,2008,24(5):717- 718.
    [23] Betaneourt AA.Phase I clinical trial in healthy adults of a nasalvaccine candidate containing recombinant hepatitis B surface and core antigens[J].Int J Infect Dis,2007,11(5):394-401.
    [24] Hu ZB, Liu Y, Zhai XJ, et al.New loci associated with chronic hepatitis B virus infection in Han Chinese[J].Nat Genet,2013,45(12):1499-1503.
    [25] Rehermann B.IntrahepaticT cells in Hepatitis B:viral control versus liver cell injury[J].J Exp Med,2000,191:1263-1268.
    [26] Bertoletti A,Ferrari C.Kinetics of the immune response during HBV and HCV infection[J].Hepatology,2003,38(1):4-13.
    [27] Shiina S, Fujino H, Uta Y, et al.Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I: analysis of 1744 HBsAg carriers[J].Am J Gastroenterol, 1991,86(7):866-871.
    [28] Chen X, Tang Y, Zhang Y,et al.Peietal Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo[J].Lab Invest, 2014,94(5):478-490.
    [29] Pan XW, Ding HG, Zhou XY,et al.Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*33:03 in peripheral blood mononuclear cells from patients and transgenic mice[J].Biochem Biophys Res Commun,2014,449:135-140.
    [30] Ito H, Hoshi M, Ohtaki H,et al. Ability of IDO to attenuate liver injury in a-galactosylceramide-induced hepatitis model[J].J Immunol,2010,185(8):4554-4560.
    [31] Ito H, Seishima M. Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell[J]. Biomed Biotechnol,2010,10:641-757.
    [32] Kim D, Hung CF, Wu TC,et al. DNA vaccine with a-galactosylceramide at primephase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells[J]. Vaccine,2010, 28:7297-305.
    [33] Ito H, Ando K, Ishikawa T, et al. Role of Va14+ NKT cells in the development of hepatitis B virus-specific CTL: activation of Va14+ NKT cells promotes the breakage of CTL tolerance[J]. Int Immunol,2008,20:869-879.
    [34] Akbar SM, Chen S, Al-Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccinesin a murine model of chronic hepatitis B: HBcAg is a candidate for atherapeutic vaccine against hepatitis B virus[J]. Antiviral Res,2012,96:59-64.
    [35] Chen W, Shi M, Shi F, et al. HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes[J]. Hepatol Res,2009,39:355-365.
    [36] Chen X, Liu H, Tang Z, et al. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellular delivered CTL epitopes via cytoplasmic transduction peptide[J]. Acta Biochim Biophys Sin(ABBS,Shanghai), 2013,45(3):203-212.
  • [1] 沈启刚, 韩宗儒, 闵晓春, 姚勤, 马维娜.  中医辨证联合恩替卡韦治疗慢性乙型肝炎的临床疗效观察 . 药学实践与服务, 2020, 38(2): 170-173. doi: 10.3969/j.issn.1006-0111.201904148
    [2] 邬亚妙, 姜秀浓.  腺苷蛋氨酸治疗慢性乙型肝炎伴胆红素升高疗效观察 . 药学实践与服务, 2015, 33(5): 457-459. doi: 10.3969/j.issn.1006-0111.2015.05.021
    [3] 林惊世.  3种核苷类似物治疗慢性乙型肝炎的成本-效果分析 . 药学实践与服务, 2011, 29(6): 475-477.
    [4] 于洪亮, 唐立尧, 魏斌.  4种常见中药治疗乙肝的研究进展 . 药学实践与服务, 2006, (1): 31-34.
    [5] 徐国华, 雷招宝.  治疗慢性丙型肝炎新药——聚乙二醇干扰素α-2b . 药学实践与服务, 2005, (6): 350-353.
    [6] 劳国琴, 唐志华, 王佳良.  4种慢性乙型肝炎治疗方案的成本-效果分析 . 药学实践与服务, 2004, (6): 374-376.
    [7] 张夏华, 龚守军, 吴征.  乙肝康治疗慢性乙型肝炎近期疗效分析 . 药学实践与服务, 2004, (3): 148-149.
    [8] 顾晶晶, 田桂珍.  拉米夫定联合苦参素治疗慢性乙型肝炎的临床疗效 . 药学实践与服务, 2003, (1): 3-4.
    [9] 吴诚, 钟延强, 刘善奎.  干扰素缓释给药系统的研究进展 . 药学实践与服务, 2003, (2): 87-89.
    [10] 张晓莉, 田桂珍, 顾晶晶.  疗尔健(Hepadif)治疗慢性乙型肝炎临床观察 . 药学实践与服务, 2001, (5): 262-263.
    [11] 王雪, 陈泽莲.  干扰素口含片及其它非注射用干扰素制剂的研究进展及临床应用 . 药学实践与服务, 1999, (5): 274-275.
    [12] 郭德玉, 程珊, 李秀兰.  干扰素与聚肌胞合用对乙型肝炎30例HBV转归疗效观察 . 药学实践与服务, 1999, (2): 121-121.
    [13] 林剑梅, 黄啸坤, 范丽萍.  干扰素滴眼液辅助治疗尖锐湿疣 . 药学实践与服务, 1999, (6): 328-329.
    [14] 杨以真, 蔡修熙.  干扰素不适用于流行性腮腺炎的治疗 . 药学实践与服务, 1998, (5): 281-282.
    [15] 朱光文, 李东.  四君子汤加减治疗难治性慢性乙型肝炎33例疗效观察 . 药学实践与服务, 1997, (2): 82-83.
    [16] 高乃武, 李汉章.  乙肝Ⅰ号治疗慢性乙型肝炎疗效观察 . 药学实践与服务, 1997, (1): 9-10.
    [17] 何仁贵, 卢存运.  猪苓多糖注射液合用乙型肝炎疫苗对慢性乙型肝炎的疗效观察 . 药学实践与服务, 1996, (3): 142-144.
    [18] 刘丽萍, 徐丽芬.  基因工程干扰素治疗乙型病毒性肝炎34例的近期疗效和不良反应观察 . 药学实践与服务, 1995, (5): 271-272.
    [19] 陆定奕.  中草药治疗乙型肝炎的应用研究 . 药学实践与服务, 1994, (4): 21-24.
    [20] 刘能德, 刘波, 徐初洪.  国外干扰素治疗作用研究的近年报道 . 药学实践与服务, 1990, (1): 9-10.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2740
  • HTML全文浏览量:  257
  • PDF下载量:  336
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-02-10
  • 修回日期:  2015-07-13

慢性乙型肝炎的抗病毒研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.022
  • 1. 福建医科大学第一临床医学院, 福建 福州 350108;第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438
  • 2. 第二军医大学附属东方肝胆外科医院肿瘤生物治疗科、病毒基因治疗实验室, 上海 200438
  • 收稿日期: 2015-02-10
  • 修回日期: 2015-07-13

摘要: 慢性乙型肝炎是由乙型肝炎病毒(hepatitis B virus,HBV)引起的全球性传染病,HBV感染是我国肝硬化、原发性肝癌的重要原因。目前,干扰素类与核苷(酸)类似物抗病毒药物已广泛应用于临床,在一定程度上抑制了病毒的复制并控制了疾病的发展,但仍未从根本上清除病毒;各种治疗性疫苗在抗HBV方面也取得了一定疗效,但临床效果不佳。目前不少研究结果表明,生物免疫治疗可以成功清除体内的HBV,从而为乙肝的治疗带来新的希望。

English Abstract

操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
引用本文: 操跃, 钱其军. 慢性乙型肝炎的抗病毒研究进展[J]. 药学实践与服务, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu
CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
Citation: CAO Yue, QIAN Qijun. Progress in study of antiviral effect of chronic hepatitis B[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 561-565. doi: 10.3969/j.issn.1006-0111.2015.06.022
shu

    全文HTML

参考文献 (36)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计